Merck to Acquire Investigational B-Cell Depletion Therapy CN201 from Curon Biopharmaceutical

WEB RAHWAY, N.J. -- BUSINESS WIRE -- Aug. 9, 2024

MRK has announced its intent to acquire CN201, an investigational bispecific antibody created by Curon Biopharmaceutical.

MRK has agreed to acquire an investigational B-cell depletion therapy CN201 from Shanghai-based biopharma company.

CN201 is a next-generation CD3xCD19 bispecific antibody that augments and diversifies Merck's pipeline with potential applications in...